{"id":66223,"date":"2026-04-01T15:08:25","date_gmt":"2026-04-01T09:38:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=66223"},"modified":"2026-04-01T15:08:27","modified_gmt":"2026-04-01T09:38:27","slug":"sun-pharmaceutical-q4-results-date-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/","title":{"rendered":"Sun Pharmaceutical Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Sun Pharmaceutical Q4 Results FY26 \u2014 Board meeting on May 12, 2026 (Expected)<\/p><p>The Sun Pharma Q4 results 2026 is set to be one of the most closely watched earnings events of the April-May 2026 results season. With results scheduled for May 12, 2026 (Expected), investors and analysts across brokerages are building their expectations around revenue, PAT, margin trajectory, and what management will say about FY27.<\/p><p>Sun Pharmaceutical enters Q4 FY26 at a CMP of ~Rs. 1,680, against a 52-week high of Rs. 1,960 and a 52-week low of Rs. 1,440. The one-year return stands at -5%, making this quarter&#8217;s result and guidance commentary particularly important for investors deciding whether to hold, add, or exit.<\/p><p>This article covers the Sun Pharmaceutical Q4 results 2026 date, earnings estimates, key factors driving performance, five risks to watch, analyst ratings and price targets, and a full set of FAQs around what investors are searching for ahead of the announcement.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Sun_Pharmaceutical_Q4_Results_2026_Date\" title=\"Sun Pharmaceutical Q4 Results 2026 Date\">Sun Pharmaceutical Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Sun_Pharmaceutical_Q4_FY26_Earnings_Estimates\" title=\"Sun Pharmaceutical Q4 FY26 Earnings Estimates\">Sun Pharmaceutical Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#5_Key_Factors_That_Will_Drive_Sun_Pharmaceutical_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Sun Pharmaceutical Q4 FY26 Performance\">5 Key Factors That Will Drive Sun Pharmaceutical Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#US_Specialty_Revenue_%E2%80%94_Ilumya_and_Winlevi_Growth\" title=\"US Specialty Revenue \u2014 Ilumya and Winlevi Growth\">US Specialty Revenue \u2014 Ilumya and Winlevi Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#India_Formulations_Business\" title=\"India Formulations Business\">India Formulations Business<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#R_D_Pipeline_%E2%80%94_Clinical_Stage_Assets\" title=\"R&amp;D Pipeline \u2014 Clinical Stage Assets\">R&amp;D Pipeline \u2014 Clinical Stage Assets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#US_Generics_Base_Business_Stability\" title=\"US Generics Base Business Stability\">US Generics Base Business Stability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Emerging_Markets_%E2%80%94_Rest_of_World_Revenue\" title=\"Emerging Markets \u2014 Rest of World Revenue\">Emerging Markets \u2014 Rest of World Revenue<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#5_Risks_to_Watch_in_Sun_Pharmaceutical_Q4_FY26\" title=\"5 Risks to Watch in Sun Pharmaceutical Q4 FY26\">5 Risks to Watch in Sun Pharmaceutical Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#US_FDA_Warning_Letter_or_Import_Alert_Risk\" title=\"US FDA Warning Letter or Import Alert Risk\">US FDA Warning Letter or Import Alert Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Specialty_Product_Pricing_Pressure\" title=\"Specialty Product Pricing Pressure\">Specialty Product Pricing Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#R_D_Failure_Risk_%E2%80%94_Pipeline_Assets\" title=\"R&amp;D Failure Risk \u2014 Pipeline Assets\">R&amp;D Failure Risk \u2014 Pipeline Assets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Currency_Risk_%E2%80%94_USD_Revenue_Reporting\" title=\"Currency Risk \u2014 USD Revenue Reporting\">Currency Risk \u2014 USD Revenue Reporting<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Competition_in_Specialty_Dermatology\" title=\"Competition in Specialty Dermatology\">Competition in Specialty Dermatology<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Sun_Pharmaceutical_Share_Price_and_Analyst_Ratings\" title=\"Sun Pharmaceutical Share Price and Analyst Ratings\">Sun Pharmaceutical Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#What_is_the_Sun_Pharmaceutical_Q4_results_2026_date\" title=\"What is the Sun Pharmaceutical Q4 results 2026 date?\">What is the Sun Pharmaceutical Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#What_is_the_Sun_Pharmaceutical_Q4_FY26_PAT_estimate\" title=\"What is the Sun Pharmaceutical Q4 FY26 PAT estimate?\">What is the Sun Pharmaceutical Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#What_is_Sun_Pharmaceuticals_current_share_price_ahead_of_Q4_results\" title=\"What is Sun Pharmaceutical&#8217;s current share price ahead of Q4 results?\">What is Sun Pharmaceutical&#8217;s current share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Will_Sun_Pharmaceutical_declare_a_dividend_in_Q4_2026\" title=\"Will Sun Pharmaceutical declare a dividend in Q4 2026?\">Will Sun Pharmaceutical declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Which_analysts_have_a_Buy_rating_on_Sun_Pharmaceutical_before_Q4_results\" title=\"Which analysts have a Buy rating on Sun Pharmaceutical before Q4 results?\">Which analysts have a Buy rating on Sun Pharmaceutical before Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#What_were_Sun_Pharmaceutical_Q3_FY26_results\" title=\"What were Sun Pharmaceutical Q3 FY26 results?\">What were Sun Pharmaceutical Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Is_Sun_Pharmaceutical_a_good_investment_ahead_of_Q4_results\" title=\"Is Sun Pharmaceutical a good investment ahead of Q4 results?\">Is Sun Pharmaceutical a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-q4-results-date-preview\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Q4_Results_2026_Date\"><\/span><strong>Sun Pharmaceutical Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>The Sun Pharmaceutical Q4 FY26 results date is May 12, 2026 (Expected). The board of directors will meet to approve the audited financial statements for the quarter and full financial year ended March 31, 2026. The board will also consider recommending a dividend for FY26 shareholders, subject to approval at the upcoming Annual General Meeting.<\/p><p>Here is how the broader Q4 FY26 earnings calendar looks for large-cap Indian companies in April\u2013May 2026:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><\/tr><tr><td>TCS<\/td><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">April 9, 2026<\/a><\/td><\/tr><tr><td>HDFC Bank \/ ICICI Bank<\/td><td>April 18, 2026<\/td><\/tr><tr><td>HCL Technologies<\/td><td>April 21, 2026<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><\/tr><tr><td>Sun Pharmaceutical<\/td><td>May 12, 2026 (Expected)<\/td><\/tr><\/tbody><\/table><\/figure><p>Source: BSE\/NSE exchange filings, April 2026. Expected dates may change. Verify before relying.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Every quarterly result tells a story, but Sun Pharmaceutical Q4 FY26 carries more weight than a routine earnings print. Sun Pharma Q4 FY26 results in May 2026 will validate whether the US specialty pivot is genuinely transforming the company&#8217;s earnings quality.<\/p><p>The market is also watching closely because Q4 is the full-year wrap-up quarter \u2014 meaning the annual results, dividend recommendation, and FY27 outlook commentary all arrive on the same date. Management tone on demand environment, pricing, and deal pipeline will shape investor expectations for the next 6\u201312 months, not just the next quarter.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Q4_FY26_Earnings_Estimates\"><\/span><strong>Sun Pharmaceutical Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27.jpeg\" alt=\"Sun Pharmaceutical Q4 FY26 Earnings Estimates\" class=\"wp-image-66225\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Sun Pharmaceutical Q4 FY26 \u2014 Revenue, PAT, margin and growth estimates from leading brokerages<\/p><p>Access premium research pieces and stock recommendations on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Here is what leading brokerages are estimating for Sun Pharmaceutical Q4 FY26 results:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 (Actual)<\/strong><\/td><td><strong>Q4 FY26 (Estimate)<\/strong><\/td><\/tr><tr><td>Revenue (Rs. Cr)<\/td><td>13,326<\/td><td>Rs. 13,800 \u2013 14,700<\/td><\/tr><tr><td>Net Profit \/ PAT (Rs. Cr)<\/td><td>2,893<\/td><td>Rs. 2,800 \u2013 3,300<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 27.2%<\/td><td>EBITDA 26 \u2013 28%<\/td><\/tr><tr><td>CC \/ Volume Growth<\/td><td>Prior quarter<\/td><td>+6\u201310% Revenue YoY (est.)<\/td><\/tr><tr><td>Dividend (FY26)<\/td><td>Rs. 5.5\/share (FY26 interim)<\/td><td>Rs. 4 \u2013 6 final (est.)<\/td><\/tr><\/tbody><\/table><\/figure><p>Estimates compiled from MOFSL, YES Securities, JM Financial. Actual figures from NSE\/BSE filings. Verify before investing.<\/p><p>The estimates above represent analyst consensus. Actual results could diverge \u2014 positively or negatively \u2014 based on one-time items, currency movements, and sector-specific developments. The key number to watch, beyond the headline PAT, is management&#8217;s commentary on FY27 guidance.<\/p><p>Screen and track <a href=\"https:\/\/univest.in\/screeners\">Sun Pharmaceutical fundamentals on Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Sun_Pharmaceutical_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Sun Pharmaceutical Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Specialty_Revenue_%E2%80%94_Ilumya_and_Winlevi_Growth\"><\/span><strong>US Specialty Revenue \u2014 Ilumya and Winlevi Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s US specialty business is its most important growth driver and margin contributor. Ilumya (tildrakizumab, for psoriasis) and Winlevi (clascoterone, for acne) are the flagship specialty products. Q4 prescription data and net revenue realisation from these products will determine whether the US specialty narrative continues to gain momentum.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"India_Formulations_Business\"><\/span><strong>India Formulations Business<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>India domestic formulations contribute approximately 30% of revenue and are growing at 10\u201312% YoY. Q4 typically benefits from seasonal demand patterns \u2014 particularly in dermatology and cardiovascular therapy areas where Sun Pharma is market-leading. Analyst consensus expects steady 10%+ growth.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"R_D_Pipeline_%E2%80%94_Clinical_Stage_Assets\"><\/span><strong>R&amp;D Pipeline \u2014 Clinical Stage Assets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma has a meaningful late-stage R&amp;D pipeline in dermatology and ophthalmology. Any Phase 3 clinical data readouts or regulatory filings (ANDA, NDA) in Q4 would be a positive catalyst. The company spends approximately 8\u20139% of revenue on R&amp;D annually \u2014 one of the highest ratios in Indian pharma.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Generics_Base_Business_Stability\"><\/span><strong>US Generics Base Business Stability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The generics business in the US \u2014 while commoditised \u2014 provides revenue scale. Stable pricing and volume in the generics portfolio in Q4 allows Sun Pharma to continue funding its specialty build-up without EPS dilution.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Markets_%E2%80%94_Rest_of_World_Revenue\"><\/span><strong>Emerging Markets \u2014 Rest of World Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma has meaningful revenue from emerging markets \u2014 particularly Russia, MENA, and Southeast Asia \u2014 that provide geographic diversification. Q4 performance in these markets, which have been less affected by IT sector uncertainties, will support overall revenue growth.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Sun_Pharmaceutical_Q4_FY26\"><\/span><strong>5 Risks to Watch in Sun Pharmaceutical Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_FDA_Warning_Letter_or_Import_Alert_Risk\"><\/span><strong>US FDA Warning Letter or Import Alert Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Regulatory risk is the most significant binary risk for any Indian pharmaceutical company. A US FDA warning letter or import alert on any Sun Pharma manufacturing facility \u2014 particularly its specialty manufacturing plants \u2014 would have an immediate and material impact on US revenue.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Specialty_Product_Pricing_Pressure\"><\/span><strong>Specialty Product Pricing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US specialty drug pricing is under increasing legislative and commercial scrutiny. Medicare drug price negotiation, PBM pricing pressures, and biosimilar competition (for biologics in the pipeline) are long-term headwinds for the pricing power of specialty drugs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"R_D_Failure_Risk_%E2%80%94_Pipeline_Assets\"><\/span><strong>R&amp;D Failure Risk \u2014 Pipeline Assets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Clinical-stage pharmaceutical assets carry inherent failure risk. Any Phase 3 clinical trial failure in Sun Pharma&#8217;s dermatology or ophthalmology pipeline would write off years of R&amp;D investment and remove a key growth driver from the long-term model.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Currency_Risk_%E2%80%94_USD_Revenue_Reporting\"><\/span><strong>Currency Risk \u2014 USD Revenue Reporting<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma earns approximately 50% of revenue in USD and other foreign currencies. A strengthening INR would reduce reported revenue and PAT in rupee terms, even if operational performance is strong.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Competition_in_Specialty_Dermatology\"><\/span><strong>Competition in Specialty Dermatology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The psoriasis market \u2014 where Ilumya competes \u2014 has multiple strong competitors including Humira biosimilars, Skyrizi, and Tremfya. Maintaining and growing Ilumya&#8217;s market share requires continued investment in medical affairs and direct-to-physician marketing, which limits operating leverage.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Share_Price_and_Analyst_Ratings\"><\/span><strong>Sun Pharmaceutical Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28.jpeg\" alt=\"Sun Pharmaceutical Share Price and Analyst Ratings\" class=\"wp-image-66226\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Sun Pharmaceutical share price snapshot and analyst ratings heading into Q4 FY26 results<\/p><p>Sun Pharmaceutical shares are trading at ~Rs. 1,680 as of late March 2026. The 52-week high stands at Rs. 1,960 and the 52-week low at Rs. 1,440. One-year return is -5%, against a market cap of ~Rs. 4.03 Lakh Cr.<\/p><p>Here is where leading brokerages stand on Sun Pharmaceutical heading into Q4 FY26 results:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Key Thesis<\/strong><\/td><\/tr><tr><td>Motilal Oswal<\/td><td>Buy<\/td><td>Rs. 1,980<\/td><td>Specialty portfolio driving US margin expansion<\/td><\/tr><tr><td>CLSA<\/td><td>Outperform<\/td><td>Rs. 2,050<\/td><td>Ilumya + Winlevi: multi-year specialty growth<\/td><\/tr><tr><td>Kotak Institutional<\/td><td>Buy<\/td><td>Rs. 1,900<\/td><td>India formulations + US generics balance<\/td><\/tr><tr><td>Bernstein<\/td><td>Outperform<\/td><td>Rs. 1,950<\/td><td>Best-in-class Indian pharma; R&amp;D optionality<\/td><\/tr><\/tbody><\/table><\/figure><p>Source: Publicly available analyst notes, March\u2013April 2026. For informational purposes only.<\/p><p>For live TCS, Infosys, and sectoral Q4 results coverage, download the<\/p><p><a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Download the Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get live Q4 result alerts and SEBI-registered research directly on your phone.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Sun Pharma Q4 FY26 results in May 2026 will validate whether the US specialty pivot is genuinely transforming the company&#8217;s earnings quality. Revenue of Rs.13,800\u201314,700 crore and EBITDA margins of 26\u201328% are expected. The pivotal metric is US specialty revenue growth \u2014 if Ilumya and Winlevi continue to gain share, the re-rating from a generics company to a specialty-led pharma powerhouse will continue. At Rs.1,680 and down only 5% in one year, Sun Pharma is the defensive quality pick in Indian pharma.<\/p><p>This article is for informational and educational purposes only. Investments in securities are subject to market risk. Please read all related documents before investing. Past performance is not indicative of future results.<\/p><p>For more Q4 earnings previews across IT, banking, auto, and pharma sectors, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Sun_Pharmaceutical_Q4_results_2026_date\"><\/span><strong>What is the Sun Pharmaceutical Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Sun Pharmaceutical Q4 results 2026 date is May 12, 2026 (Expected). The board will meet to approve the audited Q4 FY26 financial results \u2014 covering the quarter ended March 31, 2026 \u2014 and will consider a dividend recommendation for FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Sun_Pharmaceutical_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Sun Pharmaceutical Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Sun Pharmaceutical Q4 FY26 net profit (PAT) in the range of Rs.Rs. 2,800 \u2013 3,300 crore. This estimate is based on revenue assumptions of Rs.Rs. 13,800 \u2013 14,700 crore and a margin of EBITDA 26 \u2013 28%. Actual results may differ from these consensus estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmaceuticals_current_share_price_ahead_of_Q4_results\"><\/span><strong>What is Sun Pharmaceutical&#8217;s current share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharmaceutical shares are trading at approximately ~Rs. 1,680 as of late March 2026. The 52-week high is Rs. 1,960 and the 52-week low is Rs. 1,440. The one-year return is -5% and the market cap stands at ~Rs. 4.03 Lakh Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Sun_Pharmaceutical_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Sun Pharmaceutical declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharmaceutical is expected to consider a dividend recommendation at the May 12, 2026 (Expected) board meeting. FY26 dividends paid so far total Rs. 5.5\/share (FY26 interim). Analysts estimate the Q4 final or additional dividend at Rs. 4 \u2013 6 final (est.) per share, subject to board approval and shareholder ratification at the AGM.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Sun_Pharmaceutical_before_Q4_results\"><\/span><strong>Which analysts have a Buy rating on Sun Pharmaceutical before Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Motilal Oswal (Buy, TP: Rs. 1,980); CLSA (Outperform, TP: Rs. 2,050); Kotak Institutional (Buy, TP: Rs. 1,900); Bernstein (Outperform, TP: Rs. 1,950). These ratings are based on publicly available analyst notes from March\u2013April 2026. They are for informational purposes only and not a recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Sun_Pharmaceutical_Q3_FY26_results\"><\/span><strong>What were Sun Pharmaceutical Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharmaceutical Q3 FY26 results showed revenue of Rs.13,326 crore and PAT of Rs.2,893 crore. Margins were at EBITDA 27.2%. Q4 is expected to show a different picture \u2014 review the estimates table in this article for full expectations.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS Q4 results 2026 date is April 9, 2026. <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys Q4 results<\/a> date is April 23, 2026. HCL Technologies reports on April 21. Read full Q4 previews for all these companies on <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Sun_Pharmaceutical_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Sun Pharmaceutical a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite, investment horizon, and portfolio context. Sun Pharmaceutical has both compelling factors and genuine near-term risks \u2014 both are covered in detail in this article. Consult a SEBI-registered financial advisor before making any investment decision. Use the Univest Screener to assess Sun Pharmaceutical fundamentals independently before investing.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings, MOFSL, YES Securities, JM Financial, Screener.in and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span><strong>Recent Articles<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-date-preview\">Infosys Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/best-agrolife-q4-fy26-results-expectations\">Best Agrolife Q4 FY26 Results Preview &amp; Earnings Expectations<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/bhansali-engineering-polymers-q4-fy26-results-expectations\">Bhansali Engineering Polymers Q4 FY26 Results Preview &amp; Earnings Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/berger-paints-q4-fy26-results-expectations\">Berger Paints Q4 FY26 Results Preview &amp; Earnings Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/beml-q4-fy26-results-expectations\">BEML Q4 FY26 Results Preview &amp; Earnings Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Q4 Results FY26 \u2014 Board meeting on May 12, 2026 (Expected) The Sun Pharma Q4 results 2026 is set to be one of the most closely watched earnings events of the April-May 2026 results season. With results scheduled for May 12, 2026 (Expected), investors and analysts across brokerages are building their expectations around<\/p>\n","protected":false},"author":29,"featured_media":66227,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3965],"class_list":["post-66223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-sun-pharmaceutical-q4-results"],"metadata":{"_edit_lock":["1775036356:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:4:{s:61:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-27.jpeg\";a:2:{s:2:\"id\";i:66225;s:11:\"source_type\";s:13:\"media-library\";}s:93:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-27.jpeg\";a:2:{s:2:\"id\";i:66225;s:11:\"source_type\";s:13:\"media-library\";}s:61:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-28.jpeg\";a:2:{s:2:\"id\";i:66226;s:11:\"source_type\";s:13:\"media-library\";}s:93:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150454\/image-28.jpeg\";a:2:{s:2:\"id\";i:66226;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["71"],"rank_math_description":["Sun Pharma Q4 results 2026 preview \u2014 US specialty revenue, PAT, R&amp;D pipeline and FY27 outlook. Full earnings preview for SUNPHARMA Q4 FY26."],"rank_math_title":["Sun Pharma Q4 Results 2026: US Revenue, PAT &amp; Specialty Drug Outlook | Univest"],"rank_math_focus_keyword":["Sun Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["66227"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7298"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/01150642\/Sun-Pharma-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=66223"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66223\/revisions"}],"predecessor-version":[{"id":66229,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66223\/revisions\/66229"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/66227"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=66223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=66223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=66223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}